Session Abstract – PMWC 2017 Silicon Valley

Session Synopsis: Data aggregation and data sharing efforts exist all over the world yet there is no platform or ecosystem that brings all of these efforts together. What are the challenges of creating a universal approach to data sharing (such as Cancer Moonshot) versus private and/or proprietary approaches that are trying to differentiate themselves? In this session you will hear from industry leaders who have direct experience in the world of data sharing and data aggregation. You will get a better understanding of the true challenges behind data sharing efforts and what it will take to create a universal movement that will benefit all stakeholders.

Session Chair Profile

Ph.D., VP of Oncology, Illumina
Biography

John is the Vice President of Oncology, Market Development & Product Marketing for Illumina’s recently formed Oncology Business Unit. Prior to joining Illumina, John was Vice President of Commercial Strategy and Market Access for Genoptix Inc., a Novartis company where, from 2008 until 2014, he drove several functions including Marketing and Business Development, building the portfolio of oncology diagnostic services. John began his career as a scientist for Invitrogen (now Thermo Fisher Scientific) before transitioning to the business team as a marketer overseeing product management of the proteomics portfolio. He earned his Ph.D. in Molecular Genetics & Biochemistry from the University of Pittsburgh, School of Medicine in 2000, and was a National Research Service Award Scholar at the California Institute of Technology from 2000 to 2003.

Session Chair Profile

MD, MS, VP of Bioinformatics and Data Sciences, Illumina
Biography

John Shon is VP of Bioinformatics and Data Sciences at Illumina. In this role he leads a global team of bioinformatics scientists in developing algorithms and methods for Illumina NGS instruments and assays. As part of the Enterprise Informatics business unit, he also leads bioinformatics for clinical interpretation and translational informatics software. Prior to Illumina, Dr. Shon has over a decade of experience in large pharmaceutical companies, most recently as VP of Informatics, Research IT and External Innovation at Janssen Pharmaceuticals (a division of J&J) where he supported R&D, clinical development and Janssen Diagnostics teams. At Roche, Dr. Shon led informatics groups in translational research for target discovery, biomarker selection, drug safety and personalized healthcare. John earned his AB in Biochemistry from Harvard, an MD from Stanford, and completed his internship and residency in Internal Medicine at the University of Chicago, and an MS and postdoc in Medical Information Sciences at Stanford.

Speaker Profile

Ph.D., Center for Biomedical Informatics and IT, National Cancer Institute
Biography

Dr. Klemm’s activities at NCI CBIIT have focused largely on programs promoting open science, open data, and open source. She currently coordinates the NCI Informatics Technology for Cancer Research Program and is on the leadership team for the NCI Cancer Genomics Cloud Pilots. Dr. Klemm received her undergraduate degree in Biology from the University of Utah and her PhD in Biology from the Massachusetts Institute of Technology, where she performed structure-function studies of protein-DNA interactions though x-ray crystallography. She was subsequently a Jane Coffins Childs postdoctoral fellow at Stanford University, studying protein export from the nucleus during T-cell signal transduction. Prior to joining NCI in 1997, Dr. Klemm worked at Incyte Corporation where she was responsible for the management of genomic information products, and 3rd Millennium, where she served as the Head of Scientific Consulting.

Speaker Profile

M.D., CMO, Invitae
Biography

Dr. Nussbaum was chief of the Division of Genomic Medicine at UCSF Health where he also held leadership roles in the Cancer Genetics and Prevention Program beginning in January 2009 and the Program in Cardiovascular Genetics beginning in July 2007. From April 2006 to August 2015, he served as a member of the UCSF Institute for Human Genetics. Prior to joining UCSF Health, Dr. Nussbaum was chief of the Genetic Disease Research Branch of the National Human Genome Research Institute, one of the National Institutes of Health, from 1994 to 2006. He is a member of the Institute of Medicine and a fellow at the American Academy of Arts and Sciences. Dr. Nussbaum is a board-certified internist and medical geneticist who holds a B.S. in Applied Mathematics from Harvard College and an M.D. from Harvard Medical School in the Harvard-MIT joint program in Health Sciences and Technology. He completed his residency in internal medicine at Barnes-Jewish Hospital and a fellowship in medical genetics at the Baylor College of Medicine.

Speaker Profile

M.D., Ph.D., Executive Director of Precision Medicine & Precision Genomics, Intermountain Healthcare
Biography

Lincoln Nadauld, MD, PhD, is the Executive Director of Precision Medicine and Precision Genomics at Intermountain Healthcare. Dr. Nadauld recently participated in the Precision Medicine Initiative Summit and roundtables at the White House with President Barack Obama. He also attended Vice President Joe Biden’s Cancer Moonshot Summit, where the Oncology Precision Network (OPeN), spearheaded by Dr. Nadauld, was mentioned among the Vice President’s remarks. OPeN is a consortium of healthcare partners working to advance data-sharing in precision medicine, including genomic information and outcomes. Dr. Nadauld completed his undergraduate education at Brigham Young University, and went on to complete combined MD/PhD and clinical training at the University of Utah. He completed clinical training in Medical Oncology at Stanford University School of Medicine, where he completed a postdoctoral fellowship in solid tumor genomics.

Speaker Profile

President and CEO, Genetic Alliance
Biography

Sharon Terry is President and CEO of the Genetic Alliance, a network transforming health by promoting openness and is founding CEO of PXE International, a research advocacy organization for the genetic condition pseudoxanthoma elasticum (PXE). Her memberships and advisories include the International Rare Disease Research Consortium and the Institute of Medicine Science and Policy Board. She was instrumental in the passage of the Genetic Information Nondiscrimination Act. Among other awards she received was the Clinical Research Forum and Foundation’s Annual Award for Leadership in Public Advocacy in 2011.

Speaker Profile

Founder, Multiple Myeloma Research Foundation; Faculty Co-Chair, HBS Kraft Precision Medicine Accelerator
Biography

After being diagnosed with multiple myeloma in 1998, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney, founded the MMRF with the hope of one day finding a cure for this fatal blood cancer. Leveraging her past experience as a graduate of Harvard Business School and leader of a major pharmaceutical company, Kathy applied her business savvy to the science of cancer research. She and the MMRF identified barriers slowing drug development, particularly in an uncommon heterogeneous disease like multiple myeloma and developed collaborative models to overcome those obstacles. Optimized to run like a Fortune 500 company, with a culture of speed, innovation, and results—the MMRF remains laser focused on accelerating new and better treatments for patients, leading toward a cure. The success of the MMRF is a reflection of the researchers, clinicians and industry partners who have helped build game-changing models in tissue banking, genomics, clinical trials, and open access—leading not only to transforming myeloma research but becoming the blueprint for other cancer organizations around the world. Today, Giusti is extending her leadership expertise to all cancers, as Faculty Co-Chair of the Harvard Business School Kraft Precision Medicine Accelerator, a $20M endowed program funded by Robert Kraft and the Kraft Family Foundation to accelerate precision medicine. In recognition of her impact across the cancer ecosystem, Giusti has been named by Fortune, 1 of Top 3 Business Disrupters in Healthcare, #19 on Fortune’s World Greatest Leaders List and Time’s 100 Most Influential Leaders.